Diligence memo · auto-generated · as of July 3, 2026
VIN-28 Solaris Vaccines, LLC
VIN-28 Solaris Vaccines, LLC looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
VIN-28 Solaris Vaccines, LLC operates in Biotech / Pharma, based in FAYETTEVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
VIN-28 Solaris Vaccines, LLC has raised $185K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $185K on 2021-10-08.
Most recent recorded round closed around 2021-10-08.
Valuation (modeled)modeled
Provath models VIN-28 Solaris Vaccines, LLC at approximately $4.4M (range $101K–$34M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.86× the median modeled value of Pre-Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era. Within the normal band (86% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 4.7 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 14% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: AbX Biologics, Inc., BC Green Pharmaceuticals Inc., Platinum Biosciences, Inc., Anubis Bio Corp., Green Star Biosciences Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.